New hope for leukemia patients: drug aims to wipe out hidden cancer cells
NCT ID NCT05456698
First seen Nov 18, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This study tests a drug called inotuzumab ozogamicin in 31 adults with a type of leukemia (Ph-negative ALL) who achieved remission after initial chemotherapy but still have tiny amounts of cancer cells (minimal residual disease, or MRD). The goal is to see if the drug can clear these leftover cells. Participants receive the drug in cycles, and researchers monitor how well it works and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.